Vivimed Labs Limited (VIVIMEDLAB) | Financial Analysis & Statements
Vivimed Labs Limited Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
213.9M
Gross Profit
115.9M
54.19%
Operating Income
-53.0M
-24.76%
Net Income
-54.9M
-25.68%
EPS (Diluted)
₹-0.66
Balance Sheet Metrics
Total Assets
9.2B
Total Liabilities
9.6B
Shareholders Equity
-351.7M
Cash Flow Metrics
Revenue & Profitability Trend
Quarter Income Flow
Jun 30, 2025
Annual Income Flow
2025
Vivimed Labs Limited Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 1.2B | 1.5B | 1.9B | 2.4B | 8.6B |
| Cost of Goods Sold | 636.2M | 785.0M | 2.8B | 1.6B | 3.5B |
| Gross Profit | 526.5M | 705.7M | -928.7M | 717.9M | 5.1B |
| Gross Margin % | 45.3% | 47.3% | -49.6% | 30.3% | 58.8% |
| Operating Expenses | |||||
| Research & Development | 4.2M | 2.1M | 2.7M | 3.4M | 264.4M |
| Selling, General & Administrative | 170.8M | 73.6M | 208.2M | 142.8M | 653.5M |
| Other Operating Expenses | 100.0M | 161.1M | 279.5M | 188.4M | 2.9B |
| Total Operating Expenses | 275.1M | 236.8M | 490.4M | 334.6M | 3.8B |
| Operating Income | -290.0M | -148.1M | -2.1B | -261.1M | -218.9M |
| Operating Margin % | -24.9% | -9.9% | -109.9% | -11.0% | -2.5% |
| Non-Operating Items | |||||
| Interest Income | - | - | 0 | 0 | - |
| Interest Expense | 17.4M | 12.1M | 350.0M | 385.4M | 538.8M |
| Other Non-Operating Income | - | - | - | - | - |
| Pre-tax Income | -318.5M | -458.2M | -3.3B | -648.3M | -757.7M |
| Income Tax | 1.1M | -3.8M | -21.2M | 28.2M | 20.3M |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -319.6M | -454.5M | -3.3B | -676.5M | -778.0M |
| Net Margin % | -27.5% | -30.5% | -175.6% | -28.6% | -9.0% |
| Key Metrics | |||||
| EBITDA | -98.9M | 80.8M | -975.5M | -80.1M | 336.1M |
| EPS (Basic) | ₹-3.85 | ₹-5.48 | ₹-39.62 | ₹-8.16 | ₹-9.38 |
| EPS (Diluted) | ₹-3.85 | ₹-5.48 | ₹-39.62 | ₹-8.16 | ₹-9.38 |
| Basic Shares Outstanding | 82913915 | 82913915 | 82913915 | 82913915 | 82937100 |
| Diluted Shares Outstanding | 82913915 | 82913915 | 82913915 | 82913915 | 82937100 |
Income Statement Trend
Join Our India Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Vivimed Labs Limited Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 7.1M | 16.3M | 37.6M | 71.8M | 64.3M |
| Short-term Investments | 454.8M | 701.5M | 602.6M | - | - |
| Accounts Receivable | 741.1M | 828.2M | 741.6M | 873.6M | 1.1B |
| Inventory | 587.5M | 640.6M | 797.6M | 2.4B | 2.6B |
| Other Current Assets | 10.0K | 720.9M | 616.2M | 617.3M | 28.8M |
| Total Current Assets | 3.3B | 3.4B | 3.4B | 5.1B | 5.3B |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 340.8M | 338.8M | 338.8M | 469.9M | 356.0M |
| Goodwill | 1.7B | 1.7B | 1.7B | 1.7B | 1.7B |
| Intangible Assets | 1.4B | 1.4B | 1.4B | 1.4B | 1.4B |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 3.4M | -10.0K | -160.0K | -1.0K | 10.0K |
| Total Non-Current Assets | 5.9B | 6.1B | 6.6B | 7.6B | 7.6B |
| Total Assets | 9.2B | 9.5B | 10.0B | 12.7B | 12.9B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 394.2M | 440.7M | 552.3M | 418.9M | 342.5M |
| Short-term Debt | 3.1B | 3.1B | 3.2B | 3.0B | 2.7B |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 246.7M | 160.6M | 130.8M | 25.2M | 7.5M |
| Total Current Liabilities | 4.1B | 4.1B | 4.2B | 3.7B | 3.4B |
| Non-Current Liabilities | |||||
| Long-term Debt | 636.2M | 645.2M | 641.8M | 609.9M | 577.9M |
| Deferred Tax Liabilities | 86.2M | 90.3M | 95.2M | 116.8M | 86.0M |
| Other Non-Current Liabilities | 5.2M | 6.3M | 60.3M | 60.3M | 50.0M |
| Total Non-Current Liabilities | 5.5B | 5.5B | 5.3B | 5.3B | 5.2B |
| Total Liabilities | 9.6B | 9.6B | 9.6B | 9.0B | 8.6B |
| Equity | |||||
| Common Stock | 165.8M | 165.8M | 165.8M | 165.8M | 165.8M |
| Retained Earnings | -3.2B | -2.9B | -2.5B | - | 1.5B |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | -351.7M | -54.6M | 394.2M | 3.6B | 4.3B |
| Key Metrics | |||||
| Total Debt | 3.8B | 3.8B | 3.8B | 3.6B | 3.3B |
| Working Capital | -806.4M | -677.4M | -851.0M | 1.3B | 1.9B |
Balance Sheet Composition
Vivimed Labs Limited Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -315.0M | -458.2M | -3.3B | -642.8M | -757.7M |
| Depreciation & Amortization | - | - | - | - | - |
| Stock-Based Compensation | - | - | - | - | - |
| Working Capital Changes | 113.0M | 98.6M | 1.9B | 248.2M | 7.0B |
| Operating Cash Flow | -172.6M | -335.3M | -1.0B | 3.1M | 6.8B |
| Investing Activities | |||||
| Capital Expenditures | -45.3M | -20.4M | -49.7M | -164.1M | 5.2B |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | - | - | 0 | 0 | -1.1B |
| Investment Sales | - | 303.3M | 0 | 2.0B | - |
| Investing Cash Flow | -45.3M | 282.9M | -49.7M | 1.8B | 4.0B |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | -3.3B |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | - | - | - | - | - |
| Debt Repayment | - | - | - | - | - |
| Financing Cash Flow | 80.0M | - | 0 | 224.6M | -5.5B |
| Free Cash Flow | -62.8M | -260.3M | 303.5M | 111.3M | 5.7B |
| Net Change in Cash | -137.9M | -52.4M | -1.1B | 2.1B | 5.4B |
Cash Flow Trend
Vivimed Labs Limited Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-1.74
Price to Book
-1.16
Price to Sales
0.64
PEG Ratio
-0.01
Profitability Ratios
Profit Margin
-39.54%
Operating Margin
-97.25%
Return on Equity
90.88%
Return on Assets
-3.47%
Financial Health
Current Ratio
0.78
Debt to Equity
-8.01
Beta
0.74
Per Share Data
EPS (TTM)
₹-4.21
Book Value per Share
₹-5.78
Revenue per Share
₹10.66
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| VIVIMEDLAB | 556.4M | -1.74 | -1.16 | 90.88% | -39.54% | -8.01 |
| Sun Pharmaceutical | 3.9T | 36.73 | 5.15 | 15.08% | 19.21% | 6.68 |
| Divi's Laboratories | 1.7T | 67.11 | 10.82 | 14.64% | 24.04% | 0.58 |
| Sun Pharma Advanced | 46.7B | -13.65 | -13.55 | 157.88% | -53.22% | -1.21 |
| Innova Captab | 41.4B | 31.20 | 4.05 | 13.37% | 8.85% | 32.95 |
| Gujarat Themis | 35.4B | 73.73 | 13.36 | 19.64% | 29.99% | 27.04 |
Financial data is updated regularly. All figures are in the company's reporting currency.





